Clinical Trial

Serum 25(OH) Vitamin D and Total Serum Immunoglobulin E Levels in Patients With Pityriasis Alba

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 4, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
Pityriasis alba (PA) is a common, benign skin disorder occurring predominantly in children and adolescents. It is characterized by ill-defined hypopigmented macules and patches, round or oval in shape. They are most commonly located on the face (especially the cheeks), arms, and upper trunk; and they are more noticeable in people with darker skin types. Sun exposure accentuates the lesions. Patients and their parents are often anxious about the cosmetic appearance of the lesions. PA is not seasonal, although peeling may be worse in the winter (as a result of dry air in homes) and lesions may be more obvious in the spring and summer (as a result of sun exposure and darkening of the surrounding skin).No specific cause of PA has been identified. It is not contagious, and no infectious etiology has been reported. It is most common in individuals with a history of atopy, although it may occur in nonatopic individuals. In the present study, we will investigate the role of serum vitamin D levels and serum total IgE levels with development and course of PA. Plasma levels of 25(OH) vitamin D and Total serum immunoglobulin E will be determined by using ELISA technique.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2018-02-16; most recent amendment 2025-04-01.
Trial Details
NCT Number NCT03443765
Lead Sponsor Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Conditions Pityriasis Alba
Enrollment 280 participants
Start Date 2017-05-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-04-04